LRRIQ4 Activators
LRRIQ4 Activators are a diverse group of chemical compounds that enhance the functional activity of LRRIQ4, a protein predicted to have serine/threonine phosphatase activity and be involved in signal transduction. Forskolin and Rolipram, through their action of increasing intracellular cAMP levels, indirectly augment LRRIQ4 activity by activating PKA, which phosphorylates substrates involved in serine/threonine phosphatase pathways, thereby enhancing LRRIQ4's role in signal transduction. Epigallocatechin Gallate, by inhibiting competitive kinase signaling, indirectly potentiates LRRIQ4-mediated pathways, allowing for an increase in its activity. Inhibitors like Okadaic Acid and Calyculin A, which target protein phosphatases 1 and 2A, shift the cellular phosphatase balance, potentially enhancing LRRIQ4's relative phosphatase activity. This alteration in the phosphatase equilibrium can increase the prominence of LRRIQ4 in specific signaling pathways.
The activity of LRRIQ4 is further influenced by compounds that modulate intracellular calcium levels and various kinase pathways. Ionomycin and Thapsigargin, by elevating calcium levels, activate calcium-dependent signaling mechanisms, which are crucial for LRRIQ4's phosphatase activity. PMA, as a PKC activator, and LY294002, a PI3K inhibitor, modify several signaling pathways, potentially enhancing LRRIQ4's involvement in serine/threonine phosphatase-mediated signal transduction. U0126, by inhibiting MEK1/2, alters MAPK signaling, which can indirectly boost LRRIQ4's activity in related pathways. Staurosporine, despite its broad-spectrum kinase inhibition, may selectively enhance LRRIQ4 pathways by lifting inhibition on LRRIQ4-related processes. Finally, Sphingosine-1-phosphate, through its effect on sphingolipid signaling, could further potentiate LRRIQ4's role in phosphatase-mediated signal transduction, illustrating the complex interplay of these activators in modulating LRRIQ4's functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a phosphodiesterase inhibitor, increases cAMP levels in cells, similarly leading to PKA activation. This activation can influence LRRIQ4's protein serine/threonine phosphatase activity, augmenting its signal transduction role. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate, a kinase inhibitor, can indirectly increase LRRIQ4 activity by reducing competitive kinase signaling, thus potentially allowing LRRIQ4-mediated serine/threonine phosphatase pathways to be more active. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid, a potent inhibitor of protein phosphatases 1 and 2A, shifts the cellular phosphatase balance, potentially enhancing LRRIQ4's relative activity in serine/threonine dephosphorylation processes within signal transduction pathways. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A, another inhibitor of protein phosphatases 1 and 2A, similarly shifts the phosphatase balance, which could indirectly increase LRRIQ4 activity in specific signaling pathways where it functions. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin, a calcium ionophore, raises intracellular calcium levels, which can modulate various signaling pathways, potentially enhancing LRRIQ4-mediated phosphatase activity involved in signal transduction. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a PKC activator, alters various signaling pathways, including those in which LRRIQ4 is involved. This can enhance LRRIQ4's role in serine/threonine phosphatase-mediated signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, shifts signaling pathways, potentially enhancing LRRIQ4 activity by reducing competitive PI3K-Akt signaling, which can indirectly influence serine/threonine phosphatase pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, an inhibitor of MEK1/2, alters MAPK signaling. This shift can indirectly enhance LRRIQ4's phosphatase activity by affecting downstream serine/threonine phosphatase-related signaling processes. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, could selectively enhance LRRIQ4 pathways by reducing the inhibition exerted by specific kinases on LRRIQ4-related serine/threonine phosphatase processes. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate, by modulating sphingolipid signaling, can influence LRRIQ4's activity in serine/threonine phosphatase-mediated signal transduction. | ||||||